Vaxcell-Bio Therapeutics Co., Ltd.
KOE: 323990.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jae-Jung Lee
- Employees
- 81
- Headquarters
- Hwasun, South Korea
- IPO year
- 2020
- Market cap
- ₩160.1B
- Website
- https://www.vaxcell-bio.com
Loading 323990…
Loading profile data…Frequently asked questions about 323990
What does Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ) do?
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Where does 323990.KQ trade?
Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ) trades on the KOSDAQ.
What sector is 323990.KQ in?
Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vaxcell-Bio Therapeutics Co., Ltd.?
Jae-Jung Lee is the chief executive officer of Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ).
Where is Vaxcell-Bio Therapeutics Co., Ltd. headquartered?
Vaxcell-Bio Therapeutics Co., Ltd. is headquartered in South Korea.
Does 323990.KQ pay a dividend?
Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 323990.KQ go public?
Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ) completed its initial public offering in 2020.